Latent Tuberculosis Infection Diagnosis and Management

Diagnostic Evaluation and Test Interpretation

Patients with a positive QuantiFERON-TB Gold (QFT-G) test should be referred for medical and diagnostic evaluation to rule out active tuberculosis before initiating treatment for latent tuberculosis infection (LTBI), as recommended by the Centers for Disease Control and Prevention (CDC) 1
A change from negative to positive QFT-G should be considered a new infection and managed accordingly, with consideration of risk factors such as HIV status, recent TB contacts, country of origin, immunosuppression status, fibrotic changes on chest radiograph, and medical conditions like diabetes, chronic renal failure, and silicosis 2, 1
The QuantiFERON test (QFT) has higher specificity than the tuberculin skin test (TST), particularly in BCG-vaccinated individuals, making it valuable for diagnosing latent TB infection (LTBI) 3, 4
The Infectious Diseases Society of America recommends cautious test interpretation in immunocompromised patients, as false negatives may occur, and performing both QFT and TST may be useful in certain situations, such as when the initial test is negative but clinical suspicion is high 2, 5

The preferred regimens for LTBI treatment, in order of preference, are: Isoniazid + Rifapentine weekly for 3 months, Rifampin daily for 4 months, and Isoniazid daily for 9 months, with the CDC recommending these regimens based on their efficacy and safety profiles 1
First-line LTBI treatment regimen is isoniazid for 9 months, with alternative regimens including rifampin for 4 months or isoniazid plus rifapentine weekly for 3 months (directly observed therapy), as recommended by the American Thoracic Society and the CDC 4, 6, 1
The CDC recommends prioritizing LTBI treatment for HIV-infected persons, recent contacts of TB patients, and persons with fibrotic changes on chest radiograph, regardless of TST/QFT-G result, with a minimum of 12 months of isoniazid therapy 1

HIV-infected patients should be tested for latent TB infection regardless of TST results, and immunocompromised patients, such as those with HIV infection or on immunosuppressive therapy, are at higher risk of progression to active TB and should be prioritized for LTBI treatment 6, 7
Pregnant women with a positive QFT-G test result should defer treatment until after delivery unless they are at high risk of progression to active TB, in which case isoniazid with pyridoxine is preferred, and children, especially those under 5 years of age, are at higher risk of progression to active TB and should be prioritized for LTBI treatment, with dosing adjustments based on weight 6
Patients receiving anti-TNF agents like adalimumab are at risk for reactivation of latent infections, especially tuberculosis, and annual monitoring for TB is crucial, with yearly QuantiFERON-TB Gold testing for latent tuberculosis infection (LTBI) screening, especially those at high risk, as recommended by the American Academy of Dermatology 4, 8, 9

Monthly clinical assessment is necessary for patients undergoing LTBI treatment, to monitor for medication adherence, signs of hepatotoxicity, peripheral neuropathy, and other adverse effects, with laboratory monitoring, including baseline liver function tests (LFTs) and monthly LFT monitoring for high-risk patients, as recommended by the CDC 6, 4, 10, 1
Clinical improvement and other diagnostic methods, such as chest X-ray and symptom screening, should be used to assess treatment success, and QFT-G should not be used to monitor the effect of preventive therapy, as stated by the American Academy of Dermatology guidelines 4, 6